Granules Eyes Oncology After Exiting Ventures
Plans To Sit On Cash from Omnichem And Biocause Exits
Executive Summary
Granules India has ambitions to become a vertically integrated player in cancer therapies after the company ended joint ventures for contract research and manufacturing services as well as for making bulk ibuprofen.
You may also be interested in...
Granules May Be Next Private Equity Target
A recent focus on high-margin generic formulations, strong contract manufacturing business, and expected cash inflow from stake sales in joint ventures could make Granules India an attractive buy for private equity funds.
Granules India Next On PE Buy List?
A recent focus on high-margin generic formulations, strong contract manufacturing business, and expected cash inflow from stake sales in joint ventures could make Granules India an attractive buy for PE funds.
Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers
Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.